Literature DB >> 11733416

Have drug companies hyped social anxiety disorder to increase sales. No: Efforts to relieve human suffering deserve rewards.

D V Sheehan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11733416      PMCID： PMC1275957          DOI： 10.1136/ewjm.175.6.365

Source DB:  PubMed          Journal:  West J Med        ISSN： 0093-0415


× No keyword cloud information.
  5 in total

Review 1.  Social anxiety disorder.

Authors:  B A Raj; D V Sheehan
Journal:  Med Clin North Am       Date:  2001-05       Impact factor: 5.456

2.  Social anxiety disorder and the risk of depression: a prospective community study of adolescents and young adults.

Authors:  M B Stein; M Fuetsch; N Müller; M Höfler; R Lieb; H U Wittchen
Journal:  Arch Gen Psychiatry       Date:  2001-03

3.  Impact of generalized social anxiety disorder in managed care.

Authors:  D J Katzelnick; K A Kobak; T DeLeire; H J Henk; J H Greist; J R Davidson; F R Schneier; M B Stein; C P Helstad
Journal:  Am J Psychiatry       Date:  2001-12       Impact factor: 18.112

4.  Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey.

Authors:  R C Kessler; K A McGonagle; S Zhao; C B Nelson; M Hughes; S Eshleman; H U Wittchen; K S Kendler
Journal:  Arch Gen Psychiatry       Date:  1994-01

5.  Phenelzine in social phobia.

Authors:  M R Liebowitz; A J Fyer; J M Gorman; R Campeas; A Levin
Journal:  J Clin Psychopharmacol       Date:  1986-04       Impact factor: 3.153
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.